Why cancelling your private health insurance could have unintended consequences

20 January 2020 - Nick Maconachie and Anna Dimeas have very different views on private health cover. ...

Read more →

Pricing of pharmaceuticals is becoming a major challenge for health systems

13 January 2020 - Manufacturers using their market power to maximise profits results in prices that are unjustifiable and unaffordable. ...

Read more →

Defining the concept of fair pricing for medicines

13 January 2020 - Suerie Moon and colleagues consider what makes a fair price for both buyers and sellers. ...

Read more →

An evidence-based framework for identifying technologies of no or low-added value

13 December 2019 - This study's objective was to synthetise the state of the art of methods for identifying candidate technologies ...

Read more →

Value-based pricing for gene therapy? Maybe not ready for haemophilia.

12 December 2019 - Insurers grappling with the million-dollar-plus costs of gene therapy have touted "value-based" arrangements that allow payment ...

Read more →

Weighing costs and benefits in the economics of cancer care

10 December 2019 - Oncology is a profession and a calling to serve patients with cancer, but it is also an ...

Read more →

Base drug prices on value rather than R&D

8 December 2019 - For decades, R&D spending on pharmaceuticals has gone up more or less in tandem with the ...

Read more →

Using GRADE methodology to assess innovation of new medicinal products in Italy

25 November 2019 - In April 2017 the Italian Medicine Agency developed new criteria to grant any new medicinal product with ...

Read more →

ICER opens nominations for new members of its voting panels

25 November 2019 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...

Read more →

The life improvement value: a new measure of cost-efficiency

23 November 2019 - The decision not to make zoster vaccination available to people older than 79 years1 was based on ...

Read more →

Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in health technology assessment in Canada

15 November 2019 - Consideration of ethical, legal, and social issues plus patient values (ELSI+) in health technology assessment is challenging ...

Read more →

Obscure model puts a price on good health—and drives down drug costs

4 November 2109 - Concept called QALY places dollar value on the health medicines can restore; ‘starting to influence decision-making’. ...

Read more →

Report clearly demonstrates the value of vaccines

1 November 2019 - Medicines Australia welcomes today’s report from the Australian Institute of Health and Welfare which verifies the ...

Read more →

Complexity in assessing the benefit versus risk of vaccines: experience with rotavirus and dengue virus vaccines

17 October 2019 - The remarkable contribution of immunisation programs to public health is recognised by most people, including those who ...

Read more →

Some say a non-profit research group unfairly influences drug prices

16 October 2019 - Have you ever wondered how pharmaceutical companies decide whether that pill you take costs $3 or ...

Read more →